Brief: Biohaven - Completes Enrollment In Rise3 Pivotal Phase 2/3 Focal Epilepsy Study With Opakalim
30/06/2026 13:48
BRIEF-Biohaven - Completes Enrollment In Rise3 Pivotal Phase 2/3 Focal Epilepsy Study With Opakalim June 30 (Reuters) - Biohaven Ltd BHVN.N:
BIOHAVEN - COMPLETES ENROLLMENT IN RISE3 PIVOTAL PHASE 2/3 FOCAL EPILEPSY STUDY WITH OPAKALIM
BIOHAVEN - TOP-LINE RESULTS FROM RISE3 STUDY EXPECTED IN SECOND HALF OF 2026
Source text: ID:nPn5tWwWVa
Further company coverage: BHVN.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biohaven
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
Brief: Biohaven - FDA Accepts Biohaven NDA Resubmission For Vyglxia (Troriluzole) In SCA
Biohaven jumps as FDA takes second look at brain disorder drug
Brief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean